<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121690</url>
  </required_header>
  <id_info>
    <org_study_id>17200051</org_study_id>
    <nct_id>NCT03121690</nct_id>
  </id_info>
  <brief_title>The Applicability of Different Scoring Systems and Use of Steroids in the Treatment of Hospital Acquired Pneumonia</brief_title>
  <official_title>The Applicability of Different Scoring Systems and Use of Steroids in the Treatment of Hospital Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross sectional randomized clinical trial study will be done at Respiratory intensive care&#xD;
      unit and Chest department at Assiut University Hospitals on All patients who developed&#xD;
      hospital acquired pneumonia including ventilator associated pneumonia through two years&#xD;
      duration to assess the prognostic value of different severity scores including (PSI, CURB65,&#xD;
      SMART COP, IDSA/ATS and SOAR) in patients with HAP, assess platelet count as a marker for&#xD;
      severity, evaluate efficacy and safety of adjuvant systemic steroids in patients with severe&#xD;
      conditions and measurement of cortisol level to assess steroid response before&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following parameters will be recorded:&#xD;
&#xD;
        -  Demographic data: including age, sex, smoking history.&#xD;
&#xD;
        -  Clinical data: Glasgow coma scales, Co-morbidities are determined by reviewing the&#xD;
           patients' clinical histories, chest examination.&#xD;
&#xD;
        -  Vital signs: including body temperature, respiratory rate, heart rate, and arterial&#xD;
           blood pressure.&#xD;
&#xD;
        -  Oxygenation data: including arterial blood gases in fixed days (at the start, 3rd day&#xD;
           and 7th day of steroid administration), ratio of partial oxygen tension in arterial&#xD;
           blood to fraction of inspired oxygen (PaO2/FiO2 ratio).&#xD;
&#xD;
        -  Laboratory data include complete blood picture focusing on leukocytic count and&#xD;
           platelets, kidney and liver function tests, serum electrolytes, Erythrocyte&#xD;
           sedimentation rate, C reactive protein, sputum culture and cortisol level before steroid&#xD;
           administration.&#xD;
&#xD;
        -  Radiology data include chest X-ray and chest ultrasonography at the day of diagnosis and&#xD;
           at 7th day of steroid administration. Chest CT will be done if possible.&#xD;
&#xD;
      Procedures: Systemic steroids will be administered early with a dosages equivalent to&#xD;
      prednisone 40 mg/day for 7 days which is considered as a &quot;stress dose&quot; of systemic&#xD;
      corticosteroids for pneumonia. The patients will also receive the appropriate initial&#xD;
      intravenous antibiotic medication and the standard care as recommended in RICU policy.&#xD;
      Cortisol level will be measured before steroid administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Hospital mortality</measure>
    <time_frame>28 days</time_frame>
    <description>measure the predicting 28 day mortality for all included cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of ICU needing</measure>
    <time_frame>28 days</time_frame>
    <description>the need of non-invasive ventilation and mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical stability</measure>
    <time_frame>28 days</time_frame>
    <description>measure time to resolution of vital signs, ability to eat and mental status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications of hospitalization</measure>
    <time_frame>28 days</time_frame>
    <description>occurrence of complication arising during hospitalization (ARDS, shock, sepsis, major arrhythmia include atrial fibrillation and supraventricular tachycardia , renal failure, electrolyte disturbance, deep venous thrombosis and GIT bleeding).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pneumonia Hospital Acquired</condition>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisone 40 mg/day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5ml saline /day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>prednisone 40 mg/day for 7 days</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>prednisone</arm_group_label>
    <other_name>hostacortin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>5ml saline / day for 7 days</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        This study will be conducted on admitted patients aged â‰¥18 years that developed hospital&#xD;
        acquired pneumonia including ventilator associated pneumonia. Its diagnosis is confirmed by&#xD;
        developing pneumonia after 48 H of admission and they had new or progressive infiltrates on&#xD;
        the chest X-ray with one of the 3 requirements of: fever more than 37.8 C or purulent&#xD;
        sputum or leukocytosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients having lung cancer and those who hadn't the full data for scoring fulfilled.&#xD;
&#xD;
          2. Chronically immunosuppressed patients (chemotherapy, human immunodeficiency virus&#xD;
             infection, or other immunosuppressive agents).&#xD;
&#xD;
          3. Condition requiring prolonged steroid use &gt; 0.5 mg/kg/day of prednisone equivalent.&#xD;
&#xD;
          4. Major gastrointestinal bleeding within 3 months.&#xD;
&#xD;
          5. Patients with prolonged intubation and having tracheostomy.&#xD;
&#xD;
          6. Patients with neurological disorders or encephalopathy.&#xD;
&#xD;
          7. Patients with pandemic H1N1 influenza A pneumonia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Abd-Elatif bayoumi, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabab Hamed Hassan</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Rabab Hamed Hassan</investigator_full_name>
    <investigator_title>specialist of chest and tuberculosis</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

